Exicure Inc
exicuretx.comWhat Do They Do?
Pursues acquisitions and partnerships, including outside biotechnology, and holds a license to develop a stem-cell mobilization drug program for multiple myeloma patients.
10-K for FY2025, filed Mar 25, 2026On January 19, 2025, we entered into a share purchase agreement (the “Share Purchase Agreement”) with GPCR Therapeutics Inc, a Korean…View ↗
GPCR USA completed its Phase 2 clinical trial in January 2026 that focused on blood cancer patients, particularly those eligible for…View ↗
explore growth through acquisitions and transactions with potential partners that see opportunity in joining an existing, publicly-traded…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$1.1MView ↗
- ▼ −57% (Loss)
- vs −$2.6M in Q2 FY2025
-
Sep 16, 2026
Nasdaq grants more time to meet its stockholders’ equity listing requirement
The company must demonstrate compliance by December 2, 2026; Nasdaq may delist its shares if it does not.
Sources
8-K, filed Sep 16, 2026
On September 10, 2026, the Company received a letter from Nasdaq granting the Company an extension through December 2, 2026 to regain…View ↗
From historical assets to transactions
Earlier, the company was exploring licenses for its historical drug candidates alongside broader transactions. The latest report says it sold its historical biotechnology assets and focuses on acquisitions and transactions, including in industries beyond biotechnology.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 25, 2026
Added a clinical program
The earlier report described seeking transactions with potential partners. The latest report describes acquiring GPCR USA and a license and collaboration agreement to advance GPCR technologies, including a stem-cell mobilization program for multiple myeloma patients.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 25, 2026While the foregoing efforts with respect to our historical assets are continuing, we do not expect they will generate significant value for…View ↗
Loading...
